Conference Coverage
From the Journals
Staying up to date on screening may cut risk of death from CRC
Staying up to date on screening was associated with a 62% decrease in the odds of dying from colorectal cancer.
Conference Coverage
ASH 2018 coming attractions look at the big picture
Big trials, big results in malignant and nonmalignant hematologic disorders are on the program at the 2018 ASH annual meeting.
Conference Coverage
ASH preview: Studies target CAR T-cell improvements
New studies highlight the role of CAR T-cell therapies in CLL, ALL, and DLBCL.
Conference Coverage
Sickle cell disease: What to watch at ASH
Dr. Alexis Thompson, ASH president, highlighted four top studies that will be presented at the meeting.
Conference Coverage
Tofacitinib and TNF inhibitors show similar VTE rates
A review of more than 50,000 U.S. rheumatoid arthritis patients shows similar venous thromboembolism rates with tofacitinib and TNF inhibition.
Conference Coverage
Minority cancer patient scan discussions 3 minutes shorter
SAN DIEGO - Oncologists spent on average 3 minutes less with minority patients than with nonminority patients discussing a scan result related to...
Conference Coverage
Lenvatinib/Pembrolizumab shows promise in previously treated metastatic NSCLC
WASHINGTON – Interim findings from a phase 1b/2 study indicate the combination shows promising clinical activity and...
Conference Coverage
TMB measured by NGS may ID SCLC patients who will benefit from immunotherapy
WASHINGTON – Targeted next-generation sequencing may help identify SCLC patients likely to benefit from...
Conference Coverage
Monalizumab-cetuximab combo shows promise in advanced head and neck SCC
WASHINGTON – Combined monalizumab + cetuximab is safe and promotes deep, durable responses in recurrent or...
Conference Coverage
Prolonged DAPT doesn’t help left main CAD
SAN DIEGO – An analysis of the EXCEL trial shows no benefit in patients who took DAPT for 3 years, compared with those who stopped it sooner.
Conference Coverage
Immunotherapy-related toxicities may be more common than reported in trials
SAN DIEGO – Certain immune-related adverse events related to PD1/PD-L1 treatment of patients with non–small cell...